Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...

Boyang Wang on Targeting Underfunded Longevity Projects SINGAPORE, SG / ACCESS Newswire / July 16, 2025 / Immortal Dragons, a ...

The drastic cost-cutting move followa the deaths of two teenagers that forced the company to restrict usage of its gene ...

This is a developing story and will be updated as more information becomes available. | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...

Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock soared 36% in after-hours trading Wednesday after the biotech company announced a major strategic restructuring plan designed to ensure ...

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys.

The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

Sarepta Therapeutics faces a challenging period as it navigates recent setbacks with its groundbreaking gene therapy, leading ...